Karyopharm Therapeutics (KPTI) versus Its Competitors Financial Survey

Karyopharm Therapeutics (NASDAQ:KPTI) is one of 897 public companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare Karyopharm Therapeutics to related businesses based on the strength of its analyst recommendations, profitability, valuation, earnings, dividends, risk and institutional ownership.

Risk and Volatility

Karyopharm Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Karyopharm Therapeutics’ rivals have a beta of -4.82, indicating that their average stock price is 582% less volatile than the S&P 500.

Profitability

This table compares Karyopharm Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Karyopharm Therapeutics	-153.28%	N/A	-145.18%
Karyopharm Therapeutics Competitors	-2,378.17%	-221.77%	-16.01%

Analyst Recommendations

This is a summary of recent ratings and target prices for Karyopharm Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Karyopharm Therapeutics	1	2	3	1	2.57
Karyopharm Therapeutics Competitors	7742	13824	25658	1029	2.41

Karyopharm Therapeutics currently has a consensus target price of $11.50, suggesting a potential upside of 2,276.03%. As a group, “Pharmaceuticals” companies have a potential upside of 30.66%. Given Karyopharm Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Karyopharm Therapeutics is more favorable than its rivals.

Earnings and Valuation

This table compares Karyopharm Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Karyopharm Therapeutics	$146.07 million	-$196.04 million	-0.04
Karyopharm Therapeutics Competitors	$3.54 billion	$3.18 billion	550.34

Karyopharm Therapeutics’ rivals have higher revenue and earnings than Karyopharm Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Karyopharm Therapeutics beats its rivals on 7 of the 13 factors compared.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.